Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives

Cabozantinib (Cabometyx(®)) is a potent multikinase inhibitor targeting the vascular endothelial growth factor (VEGF) receptor 2, the mesenchymal-epithelial transition factor (MET) receptor, and the “anexelekto” (AXL) receptor tyrosine kinase. It is approved for the treatment of advanced hepatocellu...

Descripción completa

Detalles Bibliográficos
Autor principal: Trojan, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395054/
https://www.ncbi.nlm.nih.gov/pubmed/32671719
http://dx.doi.org/10.1007/s40265-020-01361-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395054/
https://www.ncbi.nlm.nih.gov/pubmed/32671719
http://dx.doi.org/10.1007/s40265-020-01361-5

Ejemplares similares